Abstract
Abstract Radiotherapy remains an important treatment option for both surgical and non-surgical breast cancer patients; however resistance to radiation results in tumor recurrence and metastasis. eEF2K has been reported to play a
Highlights
Breast cancer arouses public concern as the leading malignancy among women worldwide [1,2,3]
NH-125 reduces the expression of Eukaryotic elongation factor 2 kinase (eEF2K) in breast cancer cells
Dysregulation of eEF2K/eEF2 can change cell cycle distribution and contribute to cancer progression. eEF2K is reported to overexpress in the majority of cancer cells and it can tolerate stress such as starvation, hypoxia and oxidative stress
Summary
Breast cancer arouses public concern as the leading malignancy among women worldwide [1,2,3]. Despite chemotherapy and targeted therapy have developed rapidly, radiotherapy remains a critical treatment option for those non-surgical breast cancer patients [4,5]. EEF2K is a calcium/calmodulin (Ca2+/CaM) dependent Ser/Thr-kinase which is regulated extensively by posttranslational phosphorylation [10,11]. Eukaryotic elongation factor 2 kinase (eEF2K) has aroused interest as an effective target in recent years [8,9].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
